Characterization and quantification of urinary metabolic biomarkers for early response to anti-tuberculosis treatment
Development of new anti-tuberculosis (TB) therapies remains a major priority to combat this infectious disease and to prevent continued transmission of the causative agent Mycobacterium tuberculosis (Mtb). However, newly developed therapies require large, lengthy clinical trials to determine the number of treatment failures and relapses for evaluation of treatment efficacy. Biomarkers for the prediction of treatment outcome in TB patients at early time points would facilitate movement of new therapies through clinical trials. Previously, liquid chromatography-mass spectrometry (LC-MS) based ...